This Biotech Firm Has Room to Run, Even as Its Drug Royalties Are Set to Shrink

Why It Matters

The analysis shows Biogen can offset a looming royalty decline with pipeline growth, offering investors a potential upside despite a neutral market stance.

Key Takeaways

• Piper Sandler upgrades Biogen to overweight, raises target to $214.
• Ocrevus royalties to fall after 2028‑29 exclusivity loss.
• New drugs Syfovre, Empaveli and felzartamab aim to sustain growth.
• Expected EV/EBITDA multiple expansion to about 11×.
• Shares flat YTD, despite analyst consensus leaning hold.

Pulse Analysis

Biogen’s revenue engine has long been anchored by Ocrevus, the multiple‑sclerosis blockbuster that generates substantial royalty streams. As the drug approaches patent expiry in 2028‑29, analysts project a gradual erosion of those royalties, a scenario that traditionally pressures biotech valuations. However, the market’s focus is shifting toward how effectively the company can manage the life‑cycle of its assets and replace lost income with new sources.

The pipeline’s recent additions—Syfovre for retinal disease and Empaveli for rare hematologic disorders—provide immediate revenue diversification. More promising is felzartamab, a CD38‑directed antibody targeting autoimmune conditions, which could become a multi‑billion‑dollar franchise if clinical milestones are met. Piper Sandler argues that these launches, combined with disciplined cost control, will not only cushion the Ocrevus royalty dip but also drive top‑line growth, supporting a higher enterprise‑value multiple.

From an investment standpoint, the firm’s upgraded rating and a $214 price target suggest a 21% upside from current levels, outpacing the consensus of mostly hold ratings. The projected 11× EV/EBITDA multiple signals confidence in sustained earnings momentum. While the stock remains flat YTD, the convergence of new product revenue, pipeline depth, and strategic life‑cycle management positions Biogen as a potentially undervalued play in the biotech sector, provided execution risks are managed.